PMC:7243768 / 65179-67167 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T533","span":{"begin":116,"end":121},"obj":"Body_part"},{"id":"T534","span":{"begin":229,"end":244},"obj":"Body_part"},{"id":"T535","span":{"begin":466,"end":471},"obj":"Body_part"},{"id":"T536","span":{"begin":1129,"end":1135},"obj":"Body_part"},{"id":"T537","span":{"begin":1144,"end":1148},"obj":"Body_part"},{"id":"T538","span":{"begin":1494,"end":1514},"obj":"Body_part"},{"id":"T539","span":{"begin":1509,"end":1514},"obj":"Body_part"},{"id":"T540","span":{"begin":1523,"end":1529},"obj":"Body_part"},{"id":"T541","span":{"begin":1570,"end":1575},"obj":"Body_part"},{"id":"T542","span":{"begin":1779,"end":1784},"obj":"Body_part"},{"id":"T543","span":{"begin":1962,"end":1967},"obj":"Body_part"}],"attributes":[{"id":"A533","pred":"fma_id","subj":"T533","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A534","pred":"fma_id","subj":"T534","obj":"http://purl.org/sig/ont/fma/fma63841"},{"id":"A535","pred":"fma_id","subj":"T535","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A536","pred":"fma_id","subj":"T536","obj":"http://purl.org/sig/ont/fma/fma7203"},{"id":"A537","pred":"fma_id","subj":"T537","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A538","pred":"fma_id","subj":"T538","obj":"http://purl.org/sig/ont/fma/fma82841"},{"id":"A539","pred":"fma_id","subj":"T539","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A540","pred":"fma_id","subj":"T540","obj":"http://purl.org/sig/ont/fma/fma7203"},{"id":"A541","pred":"fma_id","subj":"T541","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A542","pred":"fma_id","subj":"T542","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A543","pred":"fma_id","subj":"T543","obj":"http://purl.org/sig/ont/fma/fma9670"}],"text":"7.2 SARS-CoV-2 and soluble ACE2 receptor\nACE2 is required for the degradation of Ang II to Ang (1–7), reducing the blood pressure through vasodilation. ACE2 exists as both membranous forms, which are found to be anchored to the plasma membrane and the soluble form, circulating in the bloodstream but at a lower proportion [151,152]. Besides serving as an entry point for SARS-CoV-2, the higher levels of ACE2 are required by the hypertension patient to reduce the blood pressure. Therefore, the ACE2 levels need to be maintained besides inhibiting the entry of SARS-CoV-2. Thus, the usage of human recombinant soluble ACE2 (hrsACE2) which exhibited positive results in the phase I and phased II clinical trials to elevate the soluble form of ACE2that competes with the membranous ACE2 for binding with SARS-CoV-2 and inhibits the viral entry and replication can be considered as a therapeutic option to treat COVID-19. Besides inhibiting the viral entry, it also sustains the ACE2 levels required for the degradation of Ang II [153,154].\nCurrently, hrsACE2 has been approved as a treatment option of ARDS. African green monkey kidney derived cell line; namely, Vero E6 was cultured and infected with SARS-CoV-2. Then the infected culture was added with hrsACE2 to estimate the therapeutic potential of hrsACE2. 15 h post-infection, the viral replication was found to be inhibited in a dose-dependent manner with reference to the concentration of hrsACE2 added. The addition of hrsACE2 to the embryonic stem cells derived kidney organoids comprised of proximal tubular cells and podocytes clusters infected with SARS-CoV-2 had shown to reduce the viral replication in a dose-dependent manner. No studies support the in-vivo and the therapeutic roles of hrsACE2 on the pulmonary cells upon SARS-CoV-2 infection [153,155]. Therefore, the usage of hrsACE2 can be a potential therapeutic option to inhibit the viral infection besides preserving the ACE2 levels and blood pressure in control."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T262","span":{"begin":116,"end":121},"obj":"Body_part"},{"id":"T263","span":{"begin":466,"end":471},"obj":"Body_part"},{"id":"T264","span":{"begin":1129,"end":1135},"obj":"Body_part"},{"id":"T265","span":{"begin":1523,"end":1529},"obj":"Body_part"},{"id":"T266","span":{"begin":1962,"end":1967},"obj":"Body_part"}],"attributes":[{"id":"A262","pred":"uberon_id","subj":"T262","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A263","pred":"uberon_id","subj":"T263","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A264","pred":"uberon_id","subj":"T264","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"A265","pred":"uberon_id","subj":"T265","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"A266","pred":"uberon_id","subj":"T266","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"7.2 SARS-CoV-2 and soluble ACE2 receptor\nACE2 is required for the degradation of Ang II to Ang (1–7), reducing the blood pressure through vasodilation. ACE2 exists as both membranous forms, which are found to be anchored to the plasma membrane and the soluble form, circulating in the bloodstream but at a lower proportion [151,152]. Besides serving as an entry point for SARS-CoV-2, the higher levels of ACE2 are required by the hypertension patient to reduce the blood pressure. Therefore, the ACE2 levels need to be maintained besides inhibiting the entry of SARS-CoV-2. Thus, the usage of human recombinant soluble ACE2 (hrsACE2) which exhibited positive results in the phase I and phased II clinical trials to elevate the soluble form of ACE2that competes with the membranous ACE2 for binding with SARS-CoV-2 and inhibits the viral entry and replication can be considered as a therapeutic option to treat COVID-19. Besides inhibiting the viral entry, it also sustains the ACE2 levels required for the degradation of Ang II [153,154].\nCurrently, hrsACE2 has been approved as a treatment option of ARDS. African green monkey kidney derived cell line; namely, Vero E6 was cultured and infected with SARS-CoV-2. Then the infected culture was added with hrsACE2 to estimate the therapeutic potential of hrsACE2. 15 h post-infection, the viral replication was found to be inhibited in a dose-dependent manner with reference to the concentration of hrsACE2 added. The addition of hrsACE2 to the embryonic stem cells derived kidney organoids comprised of proximal tubular cells and podocytes clusters infected with SARS-CoV-2 had shown to reduce the viral replication in a dose-dependent manner. No studies support the in-vivo and the therapeutic roles of hrsACE2 on the pulmonary cells upon SARS-CoV-2 infection [153,155]. Therefore, the usage of hrsACE2 can be a potential therapeutic option to inhibit the viral infection besides preserving the ACE2 levels and blood pressure in control."}

LitCovid-PD-MONDO

LitCovid-PD-CLO

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T85195","span":{"begin":86,"end":88},"obj":"Chemical"},{"id":"T85","span":{"begin":694,"end":696},"obj":"Chemical"},{"id":"T2639","span":{"begin":1026,"end":1028},"obj":"Chemical"}],"attributes":[{"id":"A91387","pred":"chebi_id","subj":"T85195","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A28556","pred":"chebi_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A35632","pred":"chebi_id","subj":"T2639","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"}],"text":"7.2 SARS-CoV-2 and soluble ACE2 receptor\nACE2 is required for the degradation of Ang II to Ang (1–7), reducing the blood pressure through vasodilation. ACE2 exists as both membranous forms, which are found to be anchored to the plasma membrane and the soluble form, circulating in the bloodstream but at a lower proportion [151,152]. Besides serving as an entry point for SARS-CoV-2, the higher levels of ACE2 are required by the hypertension patient to reduce the blood pressure. Therefore, the ACE2 levels need to be maintained besides inhibiting the entry of SARS-CoV-2. Thus, the usage of human recombinant soluble ACE2 (hrsACE2) which exhibited positive results in the phase I and phased II clinical trials to elevate the soluble form of ACE2that competes with the membranous ACE2 for binding with SARS-CoV-2 and inhibits the viral entry and replication can be considered as a therapeutic option to treat COVID-19. Besides inhibiting the viral entry, it also sustains the ACE2 levels required for the degradation of Ang II [153,154].\nCurrently, hrsACE2 has been approved as a treatment option of ARDS. African green monkey kidney derived cell line; namely, Vero E6 was cultured and infected with SARS-CoV-2. Then the infected culture was added with hrsACE2 to estimate the therapeutic potential of hrsACE2. 15 h post-infection, the viral replication was found to be inhibited in a dose-dependent manner with reference to the concentration of hrsACE2 added. The addition of hrsACE2 to the embryonic stem cells derived kidney organoids comprised of proximal tubular cells and podocytes clusters infected with SARS-CoV-2 had shown to reduce the viral replication in a dose-dependent manner. No studies support the in-vivo and the therapeutic roles of hrsACE2 on the pulmonary cells upon SARS-CoV-2 infection [153,155]. Therefore, the usage of hrsACE2 can be a potential therapeutic option to inhibit the viral infection besides preserving the ACE2 levels and blood pressure in control."}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T139","span":{"begin":67,"end":78},"obj":"http://purl.obolibrary.org/obo/GO_0009056"},{"id":"T140","span":{"begin":139,"end":151},"obj":"http://purl.obolibrary.org/obo/GO_0042311"},{"id":"T141","span":{"begin":1007,"end":1018},"obj":"http://purl.obolibrary.org/obo/GO_0009056"},{"id":"T142","span":{"begin":1338,"end":1355},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T143","span":{"begin":1338,"end":1355},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T144","span":{"begin":1648,"end":1665},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T145","span":{"begin":1648,"end":1665},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T146","span":{"begin":1907,"end":1922},"obj":"http://purl.obolibrary.org/obo/GO_0016032"}],"text":"7.2 SARS-CoV-2 and soluble ACE2 receptor\nACE2 is required for the degradation of Ang II to Ang (1–7), reducing the blood pressure through vasodilation. ACE2 exists as both membranous forms, which are found to be anchored to the plasma membrane and the soluble form, circulating in the bloodstream but at a lower proportion [151,152]. Besides serving as an entry point for SARS-CoV-2, the higher levels of ACE2 are required by the hypertension patient to reduce the blood pressure. Therefore, the ACE2 levels need to be maintained besides inhibiting the entry of SARS-CoV-2. Thus, the usage of human recombinant soluble ACE2 (hrsACE2) which exhibited positive results in the phase I and phased II clinical trials to elevate the soluble form of ACE2that competes with the membranous ACE2 for binding with SARS-CoV-2 and inhibits the viral entry and replication can be considered as a therapeutic option to treat COVID-19. Besides inhibiting the viral entry, it also sustains the ACE2 levels required for the degradation of Ang II [153,154].\nCurrently, hrsACE2 has been approved as a treatment option of ARDS. African green monkey kidney derived cell line; namely, Vero E6 was cultured and infected with SARS-CoV-2. Then the infected culture was added with hrsACE2 to estimate the therapeutic potential of hrsACE2. 15 h post-infection, the viral replication was found to be inhibited in a dose-dependent manner with reference to the concentration of hrsACE2 added. The addition of hrsACE2 to the embryonic stem cells derived kidney organoids comprised of proximal tubular cells and podocytes clusters infected with SARS-CoV-2 had shown to reduce the viral replication in a dose-dependent manner. No studies support the in-vivo and the therapeutic roles of hrsACE2 on the pulmonary cells upon SARS-CoV-2 infection [153,155]. Therefore, the usage of hrsACE2 can be a potential therapeutic option to inhibit the viral infection besides preserving the ACE2 levels and blood pressure in control."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T482","span":{"begin":0,"end":41},"obj":"Sentence"},{"id":"T483","span":{"begin":42,"end":152},"obj":"Sentence"},{"id":"T484","span":{"begin":153,"end":334},"obj":"Sentence"},{"id":"T485","span":{"begin":335,"end":481},"obj":"Sentence"},{"id":"T486","span":{"begin":482,"end":574},"obj":"Sentence"},{"id":"T487","span":{"begin":575,"end":920},"obj":"Sentence"},{"id":"T488","span":{"begin":921,"end":1039},"obj":"Sentence"},{"id":"T489","span":{"begin":1040,"end":1107},"obj":"Sentence"},{"id":"T490","span":{"begin":1108,"end":1213},"obj":"Sentence"},{"id":"T491","span":{"begin":1214,"end":1312},"obj":"Sentence"},{"id":"T492","span":{"begin":1313,"end":1462},"obj":"Sentence"},{"id":"T493","span":{"begin":1463,"end":1693},"obj":"Sentence"},{"id":"T494","span":{"begin":1694,"end":1821},"obj":"Sentence"},{"id":"T495","span":{"begin":1822,"end":1988},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"7.2 SARS-CoV-2 and soluble ACE2 receptor\nACE2 is required for the degradation of Ang II to Ang (1–7), reducing the blood pressure through vasodilation. ACE2 exists as both membranous forms, which are found to be anchored to the plasma membrane and the soluble form, circulating in the bloodstream but at a lower proportion [151,152]. Besides serving as an entry point for SARS-CoV-2, the higher levels of ACE2 are required by the hypertension patient to reduce the blood pressure. Therefore, the ACE2 levels need to be maintained besides inhibiting the entry of SARS-CoV-2. Thus, the usage of human recombinant soluble ACE2 (hrsACE2) which exhibited positive results in the phase I and phased II clinical trials to elevate the soluble form of ACE2that competes with the membranous ACE2 for binding with SARS-CoV-2 and inhibits the viral entry and replication can be considered as a therapeutic option to treat COVID-19. Besides inhibiting the viral entry, it also sustains the ACE2 levels required for the degradation of Ang II [153,154].\nCurrently, hrsACE2 has been approved as a treatment option of ARDS. African green monkey kidney derived cell line; namely, Vero E6 was cultured and infected with SARS-CoV-2. Then the infected culture was added with hrsACE2 to estimate the therapeutic potential of hrsACE2. 15 h post-infection, the viral replication was found to be inhibited in a dose-dependent manner with reference to the concentration of hrsACE2 added. The addition of hrsACE2 to the embryonic stem cells derived kidney organoids comprised of proximal tubular cells and podocytes clusters infected with SARS-CoV-2 had shown to reduce the viral replication in a dose-dependent manner. No studies support the in-vivo and the therapeutic roles of hrsACE2 on the pulmonary cells upon SARS-CoV-2 infection [153,155]. Therefore, the usage of hrsACE2 can be a potential therapeutic option to inhibit the viral infection besides preserving the ACE2 levels and blood pressure in control."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T317","span":{"begin":431,"end":443},"obj":"Phenotype"}],"attributes":[{"id":"A317","pred":"hp_id","subj":"T317","obj":"http://purl.obolibrary.org/obo/HP_0000822"}],"text":"7.2 SARS-CoV-2 and soluble ACE2 receptor\nACE2 is required for the degradation of Ang II to Ang (1–7), reducing the blood pressure through vasodilation. ACE2 exists as both membranous forms, which are found to be anchored to the plasma membrane and the soluble form, circulating in the bloodstream but at a lower proportion [151,152]. Besides serving as an entry point for SARS-CoV-2, the higher levels of ACE2 are required by the hypertension patient to reduce the blood pressure. Therefore, the ACE2 levels need to be maintained besides inhibiting the entry of SARS-CoV-2. Thus, the usage of human recombinant soluble ACE2 (hrsACE2) which exhibited positive results in the phase I and phased II clinical trials to elevate the soluble form of ACE2that competes with the membranous ACE2 for binding with SARS-CoV-2 and inhibits the viral entry and replication can be considered as a therapeutic option to treat COVID-19. Besides inhibiting the viral entry, it also sustains the ACE2 levels required for the degradation of Ang II [153,154].\nCurrently, hrsACE2 has been approved as a treatment option of ARDS. African green monkey kidney derived cell line; namely, Vero E6 was cultured and infected with SARS-CoV-2. Then the infected culture was added with hrsACE2 to estimate the therapeutic potential of hrsACE2. 15 h post-infection, the viral replication was found to be inhibited in a dose-dependent manner with reference to the concentration of hrsACE2 added. The addition of hrsACE2 to the embryonic stem cells derived kidney organoids comprised of proximal tubular cells and podocytes clusters infected with SARS-CoV-2 had shown to reduce the viral replication in a dose-dependent manner. No studies support the in-vivo and the therapeutic roles of hrsACE2 on the pulmonary cells upon SARS-CoV-2 infection [153,155]. Therefore, the usage of hrsACE2 can be a potential therapeutic option to inhibit the viral infection besides preserving the ACE2 levels and blood pressure in control."}

2_test

{"project":"2_test","denotations":[{"id":"32450165-26552008-66451125","span":{"begin":325,"end":328},"obj":"26552008"},{"id":"32450165-19948988-66451126","span":{"begin":329,"end":332},"obj":"19948988"},{"id":"32450165-32354636-66451127","span":{"begin":1030,"end":1033},"obj":"32354636"},{"id":"32450165-32167153-66451128","span":{"begin":1034,"end":1037},"obj":"32167153"},{"id":"32450165-32354636-66451129","span":{"begin":1812,"end":1815},"obj":"32354636"},{"id":"32450165-17482553-66451130","span":{"begin":1816,"end":1819},"obj":"17482553"}],"text":"7.2 SARS-CoV-2 and soluble ACE2 receptor\nACE2 is required for the degradation of Ang II to Ang (1–7), reducing the blood pressure through vasodilation. ACE2 exists as both membranous forms, which are found to be anchored to the plasma membrane and the soluble form, circulating in the bloodstream but at a lower proportion [151,152]. Besides serving as an entry point for SARS-CoV-2, the higher levels of ACE2 are required by the hypertension patient to reduce the blood pressure. Therefore, the ACE2 levels need to be maintained besides inhibiting the entry of SARS-CoV-2. Thus, the usage of human recombinant soluble ACE2 (hrsACE2) which exhibited positive results in the phase I and phased II clinical trials to elevate the soluble form of ACE2that competes with the membranous ACE2 for binding with SARS-CoV-2 and inhibits the viral entry and replication can be considered as a therapeutic option to treat COVID-19. Besides inhibiting the viral entry, it also sustains the ACE2 levels required for the degradation of Ang II [153,154].\nCurrently, hrsACE2 has been approved as a treatment option of ARDS. African green monkey kidney derived cell line; namely, Vero E6 was cultured and infected with SARS-CoV-2. Then the infected culture was added with hrsACE2 to estimate the therapeutic potential of hrsACE2. 15 h post-infection, the viral replication was found to be inhibited in a dose-dependent manner with reference to the concentration of hrsACE2 added. The addition of hrsACE2 to the embryonic stem cells derived kidney organoids comprised of proximal tubular cells and podocytes clusters infected with SARS-CoV-2 had shown to reduce the viral replication in a dose-dependent manner. No studies support the in-vivo and the therapeutic roles of hrsACE2 on the pulmonary cells upon SARS-CoV-2 infection [153,155]. Therefore, the usage of hrsACE2 can be a potential therapeutic option to inhibit the viral infection besides preserving the ACE2 levels and blood pressure in control."}

PMC:7243768 / 65179-67167 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7243768 / 65179-67167 JSON TXT